Sunshine Biopharma (SBFM) Stock Price, Quote & News

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: (954) 330-0684

Website: sunshinebiopharma.com

Address:

333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States

Masterrunner Dec. 4 at 10:13 PM

$SBFM IMHO based on years of SBFM patterns analysis, this is going to coil and......''crash'' your dreams! 🤔

4 · Reply

contra7 Dec. 4 at 8:21 PM

$SBFM SBFM is exhibiting a textbook holding pattern—marked by tight price compression, low volume, and a lack of directional conviction. This setup is ripe for a volatility expansion, but the trigger remains elusive. This is a classic “coiled spring” setup: • No clear accumulation or distribution, but the float is so thin (~4.91) that any volume surge could trigger a sharp move. • Lack of news and post-earnings drift suggest the market is waiting for a narrative reset—PR, licensing, or regulatory movement. 🧭 Strategic Implications • Breakout Watch: A move above $1.55 on volume could trigger a squeeze toward the $1.80–$2.00 gap zone. -Co Pilot AI

0 · Reply

Havass Dec. 4 at 3:16 PM

$SBFM My request from you asking them;when do they think to reimburse losses of investors?Thank you!

2 · Reply

stockanalyzer777 Dec. 4 at 2:31 PM

$SBFM What questions do you plan on asking during investors meeting? My questions are...... 1.Inform the investors of status of research findings. 2. How will SBFM management reduce spending and increase more revenue 3. I would like MM to engage with their investors in order to increase investor confidence. How do they plan on increasing investors confidence going forward. 4. When will "we" the investors see an increase in share price. For those who cannot make to the meeting.... please type your questions so I can submit them for you. Super excited for next week!!!!!

1 · Reply

Bigwinner75 Dec. 4 at 2:47 AM

$SBFM ok forget the 47 dollars just give me the 15. Let me get the fuck out. Or I will be the biggest bear at this forum

1 · Reply

Bigwinner75 Dec. 4 at 2:32 AM

$SBFM DR has been in bed with shorts for years. Maybe it’s time for him to have some spine

0 · Reply

Bigwinner75 Dec. 4 at 2:22 AM

$SBFM burn the shorts. They deserve it

0 · Reply

Bigwinner75 Dec. 4 at 2:21 AM

$SBFM its time to burn some vicious shorts. Why this stock become to be a sex slave with them

1 · Reply

Love_To_Learn Dec. 3 at 10:41 PM

$SBFM 1.38* is me !

2 · Reply

Kalini67 Dec. 3 at 8:21 PM

$SBFM WTH I had eye surgery and didn't check the spelling🤣

0 · Reply

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Oct 28, 2025, 7:45 AM EDT - 5 weeks ago

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Oct 20, 2025, 7:45 AM EDT - 6 weeks ago

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Oct 16, 2025, 7:45 AM EDT - 7 weeks ago

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Oct 14, 2025, 10:45 AM EDT - 7 weeks ago

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Oct 14, 2025, 8:50 AM EDT - 7 weeks ago

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Oct 9, 2025, 8:00 AM EDT - 2 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Jul 2, 2025, 8:00 AM EDT - 5 months ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jun 11, 2025, 8:30 AM EDT - 6 months ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

May 15, 2025, 4:15 PM EDT - 7 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 6, 2025, 8:30 AM EDT - 7 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Apr 21, 2025, 8:30 AM EDT - 8 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 3, 2025, 10:50 AM EDT - 8 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 2, 2025, 1:20 PM EDT - 8 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 11:35 AM EDT - 8 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 1, 2025, 5:09 PM EDT - 8 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 10, 2025, 9:00 AM EDT - 9 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Jan 21, 2025, 8:00 AM EST - 11 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 15, 2025, 8:00 AM EST - 11 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Dec 9, 2024, 7:30 AM EST - 1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 4, 2024, 4:05 PM EST - 1 year ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 2, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Nov 6, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City

Nov 13, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 10, 2023, 7:35 AM EST - 3 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Jan 19, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Announces Share Repurchase Program

Dec 20, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma's Annual Letter to Shareholders

Dec 5, 2022, 5:46 PM EST - 3 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Nov 16, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Masterrunner Dec. 4 at 10:13 PM

$SBFM IMHO based on years of SBFM patterns analysis, this is going to coil and......''crash'' your dreams! 🤔

4 · Reply

contra7 Dec. 4 at 8:21 PM

0 · Reply

Havass Dec. 4 at 3:16 PM

$SBFM My request from you asking them;when do they think to reimburse losses of investors?Thank you!

2 · Reply

stockanalyzer777 Dec. 4 at 2:31 PM

1 · Reply

Bigwinner75 Dec. 4 at 2:47 AM

$SBFM ok forget the 47 dollars just give me the 15. Let me get the fuck out. Or I will be the biggest bear at this forum

1 · Reply

Bigwinner75 Dec. 4 at 2:32 AM

$SBFM DR has been in bed with shorts for years. Maybe it’s time for him to have some spine

0 · Reply

Bigwinner75 Dec. 4 at 2:22 AM

$SBFM burn the shorts. They deserve it

0 · Reply

Bigwinner75 Dec. 4 at 2:21 AM

$SBFM its time to burn some vicious shorts. Why this stock become to be a sex slave with them

1 · Reply

Love_To_Learn Dec. 3 at 10:41 PM

$SBFM 1.38* is me !

2 · Reply

Kalini67 Dec. 3 at 8:21 PM

$SBFM WTH I had eye surgery and didn't check the spelling🤣

0 · Reply

Bigwinner75 Dec. 3 at 7:56 PM

$SBFM need to revalue this stock pop to double digit. Or one is going to buy this

1 · Reply

stockanalyzer777 Dec. 3 at 7:21 PM

$SBFM The human trials should be close if those vaccines are available. I am holding for gold. You dont have to convince me twice.

2 · Reply

stockanalyzer777 Dec. 3 at 7:17 PM

$SBFM From their website: Sunshine Biopharma Inc. is a Colorado corporation headquartered in Fort Lauderdale, Florida (USA) Sunshine Biopharma Inc. is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We operate two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation with a portfolio consisting of 72 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation which develops and sells nonprescription over-the-counter (“OTC”) products. In addition, we are engaged in the development of the following proprietary drugs: (i) K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.

0 · Reply

stockanalyzer777 Dec. 3 at 7:08 PM

$SBFM 1). Link to SBFM published article https://sunshinebiopharma.com/wp-content/uploads/2024/12/JMC-Publication_20240805.pdf

0 · Reply

stockanalyzer777 Dec. 3 at 7:06 PM

$SBFM This information came from their website: In June 2021, they initiated a new research project in which they set out to determine if certain mRNA molecules can be used as anticancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology.

0 · Reply

stockanalyzer777 Dec. 3 at 6:49 PM

$SBFM Eight more days till investors meeting. I hope we get an outstanding PR prior to December 11th. SBFM is worth keeping and their stock is severely undervalued. Food for thought: SBFM is working on two research projects currently 1). treatment for Covid (by the way, they published a medical journal about this research). 2) finding a cure for liver cancer. Research looks promising. Cant wait for their human trial. They have 72 generic medications in their pipeline. Their quarterly revenue increased by 11% however, their spending is still high (hopefully this changes soon). Current shares outstanding info: Shares outstanding: 4,905,945 Insider ownership: 68.01% (≈ 3,336,652 shares) Public float (approx.): 1,569,293 shares Short interest: Currently 12.02% (≈ 589,479 shares), down from 20% (~900,000 shares) Analyst rating: Aegis rates SBFM as a Buy Target price: $7.00

1 · Reply

Suomalainen Dec. 3 at 3:12 PM

$SBFM

1 · Reply

JB197519 Dec. 3 at 5:16 AM

$SBFM Go Sunshine! They have plenty of very positive things on which to recap this year, together with a great pipeline of new products and developments in the coming year. Remember, all small caps are risky and so invest wisely. If you can’t take the heat, you’re in the wrong kitchen.

0 · Reply

stockanalyzer777 Dec. 3 at 1:13 AM

$SBFM To our Stockholders: On behalf of our Board of Directors, I cordially invite you to attend our 2025 Annual Meeting of Stockholders on December 11, 2025, at 10:00 a.m., Eastern Time, which shall be held online. During the meeting we will discuss the items of business described in the accompanying Notice of Annual Meeting and Proxy Statement, update you on important developments in our business and respond to any questions that you may have about us. Shareholder meeting information December 11th, 2025 at 10 am Below is the link. Look up SBFM https://east.virtualshareholdermeeting.com/vsm/home Does anyone know the controller number to log on?

3 · Reply

stockanalyzer777 Dec. 2 at 10:34 PM

$SBFM I AM READY FOR THE BULL RUN! THE QUESTION IS .....

2 · Reply

WhaleSharksHF Dec. 2 at 8:27 PM

$SBFM hey babes! $3 incoming when they reveal those Bitcoin dip buys! 📝 The Stats Sunshine Biopharma: generics cash cow ($45M+ ’25 rev guided). Trading at 0.15x sales while peers sit 4–8x. Forgotten, low-float, now waking up. Snapshot (Dec 1, ’25) • Price: $1.45 • MCap: $6.6M • Float: ~3.5M • Short Interest: 13% of float • CTB: 26% 💡Smart Money Two Sigma filed new 21.4k share stake (Nov 14). Fund Sentiment Score 86.1/100 — top 7% most-accumulated stocks. Quants are in. ⚡️Catalysts • Q4 earnings Jan ’26 → profitability inflection + NIOPEG biosimilar launch • K1.1 mRNA liver cancer IND H1 ’25 • SBFM-PL4 antivirals Phase 1 Q2 ’25 • 12+ new generics H2 ’25 • $10M cash + BTC treasury, zero debt 💵 Valuation $50M ’26 rev, 15% margins → ~$25M EV base case. Fair value $5.50/share. Near-term PT $3.00 (+107% from $1.45). Analyst Aegis BUY $7, consensus $7.14 (390% upside). Load the dip. DYOR. Not financial advice. Verify facts. 🚀 $CYPH $CYCN $CYCU $GPUS

0 · Reply

stockanalyzer777 Dec. 2 at 7:26 PM

$SBFM

0 · Reply

Market Cap	7.26M
Revenue (ttm)	34.87M
Net Income (ttm)	-5.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.71%
Debt to Equity Ratio	0.00

Volume	46,300
Avg Vol	941,114
Day's Range	N/A - N/A
Shares Out	4.91M
Stochastic %K	70%
Beta	1.52
Analysts	Strong Sell
Price Target	$7.00